Clinical Trials Browser

Phase 2/3 × INDUSTRY × orelabrutinib × Clear all

NCT06378138 2025-11-21

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Phase 2/3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms